

Evan J Lipson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605985/publications.pdf>

Version: 2024-02-01

80
papers

15,371
citations

87888

38
h-index

118850

62
g-index

82
all docs

82
docs citations

82
times ranked

22609
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute axillary lymphadenopathy detected shortly after COVID-19 vaccination found to be due to newly diagnosed metastatic melanoma. <i>Radiology Case Reports</i> , 2022, 17, 878-880.	0.6	5
2	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	27.0	766
3	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 303-313.	3.4	1
4	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. <i>Cancer Immunology Research</i> , 2022, 10, 885-899.	3.4	7
5	Melanoma metastatic to the hyoid bone. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 522-525.	0.5	2
6	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.	7.0	22
7	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
8	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9503-9503.	1.6	116
9	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
10	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	12.6	114
11	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
12	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. <i>Cancer Immunology Research</i> , 2021, 9, 1262-1269.	3.4	8
13	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	7.0	6
14	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 545-551.	7.0	100
15	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 1010-1021.	14.5	85
16	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020, 5, .	11.9	36
17	Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.		55
18	Kidney retransplantation after anti-“programmed cell death-1 (PD-1)“related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	4.7	20

#	ARTICLE	IF	CITATIONS
19	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.9	140
20	Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1012-1020.	1.2	13
21	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
22	681â€¦Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0
23	Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. <i>Human Pathology</i> , 2019, 91, 69-76.	2.0	14
24	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. , 2019, 7, 170.		36
25	Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. <i>Journal of Clinical Oncology</i> , 2019, 37, 2714-2718.	1.6	23
26	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
27	Poliosis Circumscripta: A Mark of Melanoma. <i>American Journal of Medicine</i> , 2019, 132, 1417-1418.	1.5	3
28	Reply. <i>Hepatology</i> , 2019, 69, 2718-2719.	7.3	0
29	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	1.6	274
30	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	3.7	127
31	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.	8.2	100
32	A Multidisciplinary Toxicity Team for Cancer Immunotherapyâ€œRelated Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 712-720.	4.9	71
33	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925.	0.8	257
34	State-of-the-Art Diagnosis and Treatment of Melanoma. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 331-339.	0.9	0
35	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
36	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.	3.4	119

#	ARTICLE	IF	CITATIONS
37	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 44-45.	0.6	0
38	Further Lessons in Pneumocystis Pneumonia Prophylaxisâ€”Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 1566.	5.1	0
39	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
40	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
41	Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. <i>Hepatology</i> , 2018, 68, 2431-2433.	7.3	20
42	From validity to clinical utility: the influence of circulating tumor <scp>DNA</scp> on melanoma patient management in a realâ€”world setting. <i>Molecular Oncology</i> , 2018, 12, 1661-1672.	4.6	32
43	Corticosteroid Use and Pneumocystis Pneumonia Prophylaxis. <i>JAMA Internal Medicine</i> , 2018, 178, 1106.	5.1	7
44	<i>BRAF</i>â€”V600 mutational status affects recurrence patterns of melanoma brain metastasis. <i>International Journal of Cancer</i> , 2017, 140, 2716-2727.	5.1	24
45	Transcriptional Mechanisms of Resistance to Antiâ€”PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	7.0	67
46	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. <i>Clinical Cancer Research</i> , 2017, 23, 4938-4944.	7.0	120
47	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
48	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630.	3.7	74
49	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 974.	7.1	65
50	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428.	5.0	209
51	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.9	317
52	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. <i>Laboratory Investigation</i> , 2017, 97, 1063-1071.	3.7	156
53	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1381-1389.	3.7	54
54	Initial efficacy of anti-lymphocyte activation gene-3 (antiâ€”LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiâ€”PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9520-9520.	1.6	188

#	ARTICLE	IF	CITATIONS
55	Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 2023.	3.3	68
56	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	27.0	1,048
57	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	5.2	524
58	Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. <i>JAMA Neurology</i> , 2016, 73, 928.	9.0	238
59	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.	27.0	244
60	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
61	Nivolumab: targeting PD-1 to bolster antitumor immunity. <i>Future Oncology</i> , 2015, 11, 1307-1326.	2.4	158
62	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	2.2	259
63	Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e69-e71.	1.6	137
64	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
65	Regulatory T cells—an important target for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 307-307.	27.6	5
66	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 24-37.	27.6	380
67	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	1.6	2,015
68	A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder. <i>Urology Case Reports</i> , 2013, 1, 2-4.	0.3	13
69	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. <i>Clinical Cancer Research</i> , 2013, 19, 462-468.	7.0	485
70	A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-4.	0.3	12
71	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. <i>Cancer Immunology Research</i> , 2013, 1, 54-63.	3.4	333
72	Re-orienting the immune system. <i>Onc Immunology</i> , 2013, 2, e23661.	4.6	29

#	ARTICLE	IF	CITATIONS
73	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	6.0	516
74	Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 431-436.	1.3	21
75	Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 6958-6962.	7.0	438
76	Art in Oncology: How Patients Add Life to Their Days. <i>Journal of Clinical Oncology</i> , 2011, 29, 1392-1393.	1.6	6
77	Lenalidomide-Induced Acute Interstitial Nephritis. <i>Oncologist</i> , 2010, 15, 961-964.	3.7	23
78	Estimating platelet production in patients with HIV-related thrombocytopenia using the immature platelet fraction. <i>American Journal of Hematology</i> , 2009, 84, 852-854.	4.1	3
79	The Immature Platelet Fraction in HIV Patients with Thrombocytopenia.. <i>Blood</i> , 2007, 110, 2095-2095.	1.4	1
80	Patient and graft outcomes following liver transplantation for sarcoidosis. <i>Clinical Transplantation</i> , 2005, 19, 487-491.	1.6	43